Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Intralumenal Vesicles and Multivesicular Bodies01:38

Intralumenal Vesicles and Multivesicular Bodies

4.4K
Intraluminal vesicles (ILVs) are small vesicles 50-80 nm in diameter formed during the maturation of early endosomes. A specialized endosome containing numerous ILVs is called a multivesicular body (MVB). ILVs contain internalized molecules such as antigens, nucleic acids, proteins, and metabolites. Some of these molecules are released from the MVBs inside exosomes and are transported to other cells. Other MVBs contain molecules that are retained in the ILVs and are later degraded within the...
4.4K
COP Coated Vesicles00:59

COP Coated Vesicles

15.3K
Membrane-enclosed structures called vesicles transport proteins and lipids across the cell. The vesicles derive their cargo from the plasma membrane, Golgi, ER, or endosome. Coated vesicles are spherical, protein-coated carriers with a 50–100 nm diameter that mediate bidirectional transport between the ER and the Golgi. The distribution of proteins between the ER and Golgi complex is dynamic and is maintained by different coated vesicles. Their formation is driven by the assembly of...
15.3K
Clathrin Coated Vesicles01:12

Clathrin Coated Vesicles

8.5K
Clathrin-coated vesicles use endocytosis to transport receptors and lysosomal hydrolases from the Golgi to the lysosome in the late secretory pathway. Clathrin-mediated endocytosis was the first described endocytic process, and Clathrin-coated vesicles remain one of the most well-studied transport vesicles. The molecular machinery that generates clathrin-coated vesicles comprises over 50 proteins that precisely coordinate vesicle formation. Cell surface receptors concentrated in indented sites...
8.5K
Vesicular Tubular Clusters01:45

Vesicular Tubular Clusters

2.8K
After budding out from the ER membrane, some COPII vesicles lose their coat and fuse with one another to form larger vesicles and interconnected tubules called vesicular tubular clusters or VTCs. These clusters constitute a compartment at the ER-Golgi interface known as ERGIC (Endoplasmic Reticulum Golgi Intermediate Compartment). The ERGIC is a mobile membrane-bound cargo transport system that sorts proteins secreted from ER and delivers them to the Golgi.
With the help of motor proteins such...
2.8K
Fusion of Secretory Vesicles with the Plasma Membrane01:26

Fusion of Secretory Vesicles with the Plasma Membrane

16.2K
Proteins and neurotransmitters in secretory vesicles can be released from a cell upon vesicle docking, priming, and fusion with the plasma membrane. Vesicles are docked and primed in preparation for the quick exocytosis of their contents in response to a stimulus. The fusion process is mainly carried out by a SNAP Receptor or SNARE complex, consisting of synaptobrevin, syntaxin-1, and SNAP-25.
In 1993, Jim Rothman proposed that the antiparallel pairing of vesicular and transmembrane SNAREs, or...
16.2K
SNAREs and Membrane Fusion01:43

SNAREs and Membrane Fusion

11.9K
Once a transport vesicle has recognized its target organelle, the vesicular membrane needs to fuse with the target membrane to unload the cargo. Transmembrane proteins called SNAREs present on organelle membranes and their vesicles, mediate vesicle fusion.
SNAREs exist in pairs that symmetrically interact and catalyze the fusion of the lipid bilayers in vesicle and target organelle. v-SNARE in the vesicle membrane are single polypeptide chains that bind to a complementary t-SNARE, composed of 2...
11.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<i>Neisseria gonorrhoeae</i>: mechanisms of immune evasion, antimicrobial resistance, and vaccine development challenges.

Frontiers in microbiology·2026
Same author

Severe anaemia and invasive bacterial infections in Kenyan children: a 26-year hospital surveillance observational study.

The Lancet. Global health·2026
Same author

Preclinical characterization of immune responses induced by a candidate gonococcal native outer membrane vesicle vaccine.

mSphere·2026
Same author

Safety and Immunogenicity of 20-valent Pneumococcal Conjugate Vaccine According to Number and Timing of Primary Series Doses.

The Pediatric infectious disease journal·2026
Same author

Understanding the impact of Klebsiella pneumoniae K-Antigen based MAPS vaccine design on the immune response in animal models.

PLoS pathogens·2026
Same author

GMMA as delivery system for Klebsiella pneumoniae O-antigens and K-antigens.

Scientific reports·2026
Same journal

Myeloid cells as sources and targets of IL-1 family cytokines in cancer.

Seminars in immunology·2026
Same journal

Interleukin-1-mediated inflammatory memory: Protective training or maladaptive tumor imprinting?

Seminars in immunology·2026
Same journal

Chronic stress at the crossroads: Decoding the HPA-SAM-immune-gut axis in inflammatory bowel disease pathogenesis and therapeutics.

Seminars in immunology·2026
Same journal

Protein tyrosine kinases in dendritic cell-mediated anti-cancer immunity.

Seminars in immunology·2026
Same journal

The immune system in Latin America and the Caribbean: Insights into diseases and diversity from local perspectives.

Seminars in immunology·2026
Same journal

Introduction to the special issue: T<sub>H</sub>9 cells in diseases.

Seminars in immunology·2026
See all related articles

Related Experiment Video

Updated: Nov 26, 2025

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria
06:38

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Published on: December 8, 2023

1.3K

Outer membrane vesicle vaccines.

Francesca Micoli1, Calman A MacLennan2

  • 1GSK Vaccines Institute for Global Health srl., Siena, Italy.

Seminars in Immunology
|December 14, 2020
PubMed
Summary
This summary is machine-generated.

Outer Membrane Vesicles (OMV) are a promising vaccine platform for bacterial pathogens. Genetic engineering enhances OMV vaccines for improved efficacy and broader protection against diseases like meningococcal B.

Keywords:
Bacterial diseasesGMMAOMVOuter membrane vesiclesVaccines

More Related Videos

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
08:07

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Published on: July 25, 2022

2.8K
In Vesiculo Synthesis of Peptide Membrane Precursors for Autonomous Vesicle Growth
07:10

In Vesiculo Synthesis of Peptide Membrane Precursors for Autonomous Vesicle Growth

Published on: June 28, 2019

5.9K

Related Experiment Videos

Last Updated: Nov 26, 2025

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria
06:38

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Published on: December 8, 2023

1.3K
A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
08:07

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Published on: July 25, 2022

2.8K
In Vesiculo Synthesis of Peptide Membrane Precursors for Autonomous Vesicle Growth
07:10

In Vesiculo Synthesis of Peptide Membrane Precursors for Autonomous Vesicle Growth

Published on: June 28, 2019

5.9K

Area of Science:

  • Vaccinology
  • Microbiology
  • Biotechnology

Background:

  • Outer Membrane Vesicles (OMV) are increasingly recognized as effective vaccine platforms against bacterial infections.
  • OMV from Neisseria meningitidis serogroup B have shown significant success, leading to licensed vaccines like 4CMenB (Bexsero).

Purpose of the Study:

  • To review advancements in the development of OMV as a vaccine delivery platform.
  • To highlight successful applications and discuss challenges and future directions in OMV vaccine technology.

Main Methods:

  • Review of existing literature and research on OMV vaccine development.
  • Analysis of genetic engineering strategies to improve OMV vaccine characteristics.

Main Results:

  • OMV vaccines have demonstrated success against Neisseria meningitidis B, with licensed products offering broad strain coverage.
  • Genetic engineering has enabled enhanced OMV vaccines with increased yields, reduced toxicity, and improved immunogenicity through antigen decoration.

Conclusions:

  • The OMV vaccine platform shows great potential for various bacterial pathogens beyond meningococcus.
  • Further research and development are needed to address challenges and fully realize the potential of OMV-based vaccines.